Ligand Pharmaceuticals (LGND) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Ligand Pharmaceuticals (LGND) do?
Ligand Pharmaceuticals Inc (LGND) is a U.S.-listed company in Healthcare (Biotechnology). What it does: Licenses drug formulation technologies and provides financing to biopharmaceutical partners. Collects milestone payments and recurring royalties on commercial product sales. It is worth $5.74B on the market and sold $253.85M over the last year.
- Market cap
- $5.74B
- P/E ratio
- 128.0×
- Annual sales
- $253.85M
- Sector
- Healthcare
- Industry
- Biotechnology
- Brief updated
- Nov 12, 2026
Brands and businesses behind LGND
- Captisol: Sells a modified cyclodextrin agent to drug makers to improve the solubility and stability of approved medicines.
LGND’s flags, in plain English
Each flag is a number from Ligand Pharmaceuticals’ reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 12, 2026.
Wide Gross Margin
Gross margin of 81.6% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Profit with Caveats
Bottom-line profit of $51M in the 12 months to Sep 30, 2026, next to $24M of profit from the business. Bottom-line profit is well above what the business itself earned. The difference came from outside day-to-day operations, such as an investment gain, a tax benefit, the sale of a business or interest on its cash. Some of these may not repeat, and they make the P/E look lower than the business alone would.
2 more risk notes open with the free trial. Try it free for 7 days.
Questions about LGND
How big is Ligand Pharmaceuticals?
Ligand Pharmaceuticals’ market cap is $5.74B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $253.85M: what customers paid the company over the last year, before any costs.
What is LGND’s P/E ratio?
LGND’s P/E ratio is 128.0×. Investors pay about 128.0 dollars for each dollar of the company’s yearly profit. A low number can mean a bargain or a problem, so read it next to the flags.
What could go wrong with LGND?
Revenue depends directly on clinical trial outcomes and commercial sales managed by outside partner companies. That is one risk on Ligand Pharmaceuticals’ card. Its first risk flag is Profit with Caveats, explained above. The card holds 2 more risk notes for trial accounts. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Ligand Pharmaceuticals’ own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. LGND’s filings on SEC.gov. The Margin Monkey is research, not advice.
